Cite
MLA Citation
Toyoaki Hida et al.. “Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.” Lancet, vol. 390, no. 10089, 2017, pp. 29–39. http://access.bl.uk/ark:/81055/vdc_100047074045.0x00005b